- Home
- MMU vs ATXS Comparison
MMU vs ATXS Comparison
Compare MMU & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMU
- ATXS
- Stock Information
- Founded
- MMU 1992
- ATXS 2008
- Country
- MMU United States
- ATXS United States
- Employees
- MMU N/A
- ATXS N/A
- Industry
- MMU Investment Managers
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- MMU Finance
- ATXS Health Care
- Exchange
- MMU Nasdaq
- ATXS Nasdaq
- Market Cap
- MMU 568.0M
- ATXS 676.1M
- IPO Year
- MMU N/A
- ATXS 2015
- Fundamental
- Price
- MMU $10.33
- ATXS $12.60
- Analyst Decision
- MMU
- ATXS Buy
- Analyst Count
- MMU 0
- ATXS 7
- Target Price
- MMU N/A
- ATXS $30.00
- AVG Volume (30 Days)
- MMU 170.7K
- ATXS 4.1M
- Earning Date
- MMU 01-01-0001
- ATXS 11-12-2025
- Dividend Yield
- MMU 4.92%
- ATXS N/A
- EPS Growth
- MMU N/A
- ATXS N/A
- EPS
- MMU N/A
- ATXS N/A
- Revenue
- MMU N/A
- ATXS N/A
- Revenue This Year
- MMU N/A
- ATXS N/A
- Revenue Next Year
- MMU N/A
- ATXS N/A
- P/E Ratio
- MMU N/A
- ATXS N/A
- Revenue Growth
- MMU N/A
- ATXS N/A
- 52 Week Low
- MMU $8.60
- ATXS $3.56
- 52 Week High
- MMU $10.45
- ATXS $12.65
- Technical
- Relative Strength Index (RSI)
- MMU 46.72
- ATXS 84.08
- Support Level
- MMU $10.40
- ATXS $12.40
- Resistance Level
- MMU $10.45
- ATXS $12.16
- Average True Range (ATR)
- MMU 0.06
- ATXS 0.29
- MACD
- MMU -0.01
- ATXS 0.10
- Stochastic Oscillator
- MMU 23.53
- ATXS 98.96
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.